<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798209</url>
  </required_header>
  <id_info>
    <org_study_id>ID-089-101</org_study_id>
    <secondary_id>2020-004464-26</secondary_id>
    <nct_id>NCT04798209</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine the safety, tolerability, and pharmacokinetics of single- and&#xD;
      multiple-ascending doses of ACT-777991 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">November 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single-center, double-blind, randomized, placebo-controlled Phase 1 study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events.</measure>
    <time_frame>From first dose on Day 1 to Day 4 after the last dose was administered</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cohorts: Maximum plasma concentration (Cmax) of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cohorts: Time to reach Cmax (tmax) of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cohorts: Terminal half-life (t1/2) of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (SAD): Absolute bioavailability of ACT-777991</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (MAD): Excretion of radioactivity in urine and feces</measure>
    <time_frame>Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (MAD): AUC during a dosing interval (AUCÏ„) following the first and the last dose of ACT-777991.</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions</measure>
    <time_frame>Blood samples will be collected at predefined time points from Day 1 to Day 4.</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A (single ascending dose) Dose A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A1 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A2 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A3 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A5 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A6 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A7 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose arm) Dose A8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A8 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) Dose B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B1 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) Dose B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B2 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) Dose B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B3 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) Dose B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B4 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) Dose B5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B5 of ACT-777991.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (single ascending dose) Absolute Bioavailability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple ascending dose) ADME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-777991 (SAD)</intervention_name>
    <description>ACT-777991 administered as hard capsules for oral use.</description>
    <arm_group_label>Part A (single ascending dose arm) Dose A2</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A3</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A4</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A5</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A6</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A7</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A8</arm_group_label>
    <arm_group_label>Part A (single ascending dose) Dose A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-777991 (MAD)</intervention_name>
    <description>ACT-777991 administered as hard capsules for oral use, once daily.</description>
    <arm_group_label>Part B (multiple ascending dose) Dose B1</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B2</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B3</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B4</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (SAD)</intervention_name>
    <description>ACT-777991 matching placebo administered as hard capsules for oral use.</description>
    <arm_group_label>Part A (single ascending dose arm) Dose A2</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A3</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A4</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A5</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A6</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A7</arm_group_label>
    <arm_group_label>Part A (single ascending dose arm) Dose A8</arm_group_label>
    <arm_group_label>Part A (single ascending dose) Dose A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (MAD)</intervention_name>
    <description>Matching placebo administered as hard capsules for oral use, once daily.</description>
    <arm_group_label>Part B (multiple ascending dose) Dose B1</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B2</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B3</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B4</arm_group_label>
    <arm_group_label>Part B (multiple ascending dose) Dose B5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)</intervention_name>
    <description>Single dose of 14C-ACT-777991 microtracer, administered intravenously.</description>
    <arm_group_label>Part A (single ascending dose) Absolute Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microtracer matching placebo (SAD - Absolute Bioavailability)</intervention_name>
    <description>Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.</description>
    <arm_group_label>Part A (single ascending dose) Absolute Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-ACT-777991 microtracer (MAD - ADME)</intervention_name>
    <description>Single dose of 14C-ACT-777991 microtracer, oral solution..</description>
    <arm_group_label>Part B (multiple ascending dose) ADME</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microtracer matching placebo (MAD - ADME)</intervention_name>
    <description>Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.</description>
    <arm_group_label>Part B (multiple ascending dose) ADME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the subject prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years&#xD;
             (inclusive) at Screening.&#xD;
&#xD;
          -  Healthy on the basis of medical history, physical examination, cardiovascular&#xD;
             assessments, and clinical laboratory tests.&#xD;
&#xD;
          -  Male subjects with a partner who might become pregnant must either be vasectomized or&#xD;
             agree to practice adequate contraception from admission to the study site until 3&#xD;
             months after dosing, or the partner must consistently and correctly use a highly&#xD;
             effective method of contraception.&#xD;
&#xD;
        Inclusion Criteria for Part B:&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at Screening&#xD;
             and a negative urine pregnancy test on Day -1. They must consistently and correctly&#xD;
             use a highly effective method of contraception with a failure rate of less than 1% per&#xD;
             year, be sexually inactive, or have a vasectomized partner.&#xD;
&#xD;
          -  Women of non-childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on Day -1.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which, in the opinion of the investigator, are likely to interfere&#xD;
             with the absorption, distribution, metabolism, or excretion of the study treatment.&#xD;
&#xD;
        Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME)&#xD;
        evaluation:&#xD;
&#xD;
          -  Radiation exposure, excluding background radiation but including diagnostic X-rays and&#xD;
             other medical exposures, exceeding 5 milli sievert (mSv) in the last 12 months or 10&#xD;
             mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant&#xD;
             Ionising Radiation Regulations, must not participate in the study.&#xD;
&#xD;
          -  Participation in any study involving administration of any Carbon-14 (14C)&#xD;
             radiolabeled compound within the 12 months prior to Screening.&#xD;
&#xD;
        Exclusion Criteria for Part B:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 588 44 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trial Disclosure Desk</last_name>
    <phone>+1 856 661 3721</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

